Pulmonary delivery for levodopa
View Patent ↗In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
1. A method of treating a patient with Parkinson's disease, that comprises:
administering to the respiratory tract of the patient particles that include about 90 weight percent or more levodopa, and a salt wherein the formulation contains less than 10% by weight of a salt, and a non-reducing sugar,
wherein the particles are delivered to the pulmonary system.
2. A method of treating a patient with Parkinson's disease, that comprises:
administering to the respiratory tract of the patient particles that consist essentially of about 90 weight percent or more levodopa, a non-reducing sugar and a salt wherein the formulation contains less than 10% by weight of the salt,
wherein the particles are delivered to the pulmonary system and have a tap density about 0.4 g/cm 3 or less, a volume median geometric diameter about 5 micrometers or more, and an aerodynamic diameter of from about 1 micrometer to about 5 micrometers.
3. The method of claim 2 , wherein the particles have an aerodynamic diameter of from about 1 micrometer to about 3 micrometers.
4. The method of claim 2 , wherein the particles have an aerodynamic diameter of from about 3 micrometer to about 5 micrometers.
5. The method of claim 2 , wherein the particles gave a tap density about 0.3 g/cm 3 or less.
6. The method of claim 2 , wherein the particles gave a tap density about 0.2 g/cm 3 or less.
7. The method of claim 2 , wherein the particles gave a tap density about 0.1 g/cm 3 or less.
8. A method of treating a patient with Parkinson's disease, that comprises:
administering to the respiratory tract of the patient particles that include about 90 weight percent or more levodopa, NaCl in an amount less than 10% by weight of NaCl, and a non-reducing sugar,
wherein the particles are delivered to the pulmonary system.
9. The method of claim 8 , wherein the non-reducing sugar is trehalose.
10. A method of delivering an effective amount of L-Dopa to the pulmonary system, comprising:
providing a mass of particles that include, by weight, about 90 percent or more L-Dopa, about 10 percent or less trehalose, and sodium chloride wherein the formulation contains about 3 percent or less sodium chloride; and administering via simultaneous dispersion and inhalation the particles, from a receptacle having the mass of the particles, to a human subject's respiratory tract.